Literature DB >> 19195908

Risk assessment in fever and neutropenia in children with cancer: What did we learn?

Esther M te Poele1, Wim J E Tissing, Willem A Kamps, Eveline S J M de Bont.   

Abstract

Children with cancer treated with chemotherapy are susceptible to bacterial infections and serious infectious complications. However, fever and neutropenia can also result from other causes, for which no antibiotic treatment is needed. In the past decades attempts have been made to stratify the heterogeneous group of pediatric cancer patients with fever and neutropenia into high- and low-risk groups for bacterial infections or infectious complications. Strategies for risk assessment have resulted in treatment regimens with early discharge or even no hospital admission at all, and/or treatment with oral or no antibiotics. We will provide a historical overview of the changing approach to low-risk fever and neutropenia, and we will also try to identify clear and objective parameters for risk assessment strategies and illustrate their relationship to innate immunity. In the future, new insights into genetic susceptibility on neutropenic fever might be of use in children with cancer with fever and neutropenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19195908     DOI: 10.1016/j.critrevonc.2008.12.009

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  10 in total

1.  Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences.

Authors:  Mohamed Badr; Tamer Hassan; Hanan Sakr; Nehad Karam; Doaa Abdel Rahman; Doaa Shahbah; Marwa Zakaria; Sahbaa Fehr
Journal:  Mol Clin Oncol       Date:  2016-07-12

2.  A Dynamic Approach for Early Risk Prediction of Gram-Negative Bloodstream Infection and Systemic Inflammatory Response Syndrome in Febrile Pediatric Hemato-Oncology Patients.

Authors:  José Antonio Villegas Rubio; Pilar Palomo Moraleda; Ana De Lucio Delgado; Gonzalo Solís Sánchez; Belén Prieto García; Corsino Rey Galán
Journal:  Children (Basel)       Date:  2022-06-03

3.  Burden, risk factors, and management of neutropenic fever among solid cancer patients in Ethiopia.

Authors:  Samuel Agegnew Wondm; Ephrem Mebratu Dagnew; Sumeya Tadesse Abegaz; Mekdes Kiflu; Bekalu Kebede
Journal:  SAGE Open Med       Date:  2022-05-19

4.  Pediatric-Oncology Simulation Training for Resident Education.

Authors:  Gayle M Smink; Donna B Jeffe; Robert J Hayashi; Noor Al-Hammadi; James J Fehr
Journal:  BMJ Simul Technol Enhanc Learn       Date:  2018-09-07

5.  Outpatient management of febrile neutropenia in children with cancer.

Authors:  Ottavio Ziino; Fabio Tucci; Mario Renato Rossi
Journal:  Pediatr Rep       Date:  2011-02-24

6.  The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia.

Authors:  Karin G E Miedema; Eveline S J M de Bont; Rob F M Oude Elferink; Michel J van Vliet; Claudi S M Oude Nijhuis; Willem A Kamps; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2010-08-28       Impact factor: 3.603

7.  A prediction model for bacteremia and transfer to intensive care in pediatric and adolescent cancer patients with febrile neutropenia.

Authors:  Muayad Alali; Anoop Mayampurath; Yangyang Dai; Allison H Bartlett
Journal:  Sci Rep       Date:  2022-05-06       Impact factor: 4.996

8.  Hospital discharges for fever and neutropenia in pediatric cancer patients: United States, 2009.

Authors:  Emily L Mueller; Kelly J Walkovich; Rajen Mody; Achamyeleh Gebremariam; Matthew M Davis
Journal:  BMC Cancer       Date:  2015-05-10       Impact factor: 4.430

9.  Adverse drug reaction-related admissions in paediatrics, a prospective single-centre study.

Authors:  Anke A G Posthumus; Carien C W Alingh; Christian C M Zwaan; Kees K van Grootheest; Lidwien L M Hanff; Bregje B C M Witjes; Geert W 't Jong; Matthijs de Hoog
Journal:  BMJ Open       Date:  2012-08-24       Impact factor: 2.692

10.  Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy.

Authors:  Mira Siegmund; Julia Pagel; Tasja Scholz; Jan Rupp; Christoph Härtel; Melchior Lauten
Journal:  Mol Cell Pediatr       Date:  2020-06-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.